{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:43:56Z","timestamp":1792601036736,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"am","delay-in-days":386,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.therap.2020.02.024","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T09:28:24Z","timestamp":1589189304000},"page":"641-647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Incretin-based drugs and intestinal obstruction: A pharmacovigilance study"],"prefix":"10.1016","volume":"75","author":[{"given":"Bastien","family":"Gudin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chayma","family":"Ladhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Babai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Hillaire-Buys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Faillie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2020.02.024_bib0145","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.therap.2020.02.024_bib0150","series-title":"Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of the meeting. 7\u201310 January 2013","author":"European Medicine Agency","year":"2013"},{"key":"10.1016\/j.therap.2020.02.024_bib0155","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/jdi.12095","article-title":"Three ileus cases associated with the use of dipeptidyl peptidase-4 inhibitors in diabetic patients","volume":"4","author":"Kanasaki","year":"2013","journal-title":"J Diabetes Investig"},{"issue":"S1","key":"10.1016\/j.therap.2020.02.024_bib0160","first-page":"311","article-title":"II-P-191: Study on six cases of intestinal obstruction during therapy with DDP-4 inhibitors. The 57th Annual Meeting of the Japan Diabetes Society","volume":"57","author":"Yoshida","year":"2014","journal-title":"J Jpn Diabetes Soc"},{"key":"10.1016\/j.therap.2020.02.024_bib0165","series-title":"Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of the meeting. 7\u201310 April 2015","author":"European Medicine Agency","year":"2015"},{"key":"10.1016\/j.therap.2020.02.024_bib0170","unstructured":"Uppsala Monitoring Centre. VigiBase. https:\/\/www.who-umc.org\/vigibase\/vigibase\/.[Accessed April 27, 2020]."},{"key":"10.1016\/j.therap.2020.02.024_bib0175","series-title":"Guideline on good pharmacovigilance practices (GVP). Module VI\u00a0\u2013\u00a0Collection, management and submission of reports of suspected adverse reactions to medicinal products","author":"EMA","year":"2017"},{"key":"10.1016\/j.therap.2020.02.024_bib0180","series-title":"Guidelines for ATC classification and DDD assignment","author":"WHO collaborating centre for drug statistics methodology","year":"2019"},{"issue":"2","key":"10.1016\/j.therap.2020.02.024_bib0185","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2020.02.024_bib0190","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapies"},{"key":"10.1016\/j.therap.2020.02.024_bib0195","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2125.1997.00615.x","article-title":"Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case\/non-case study in the French pharmacovigilance system database","volume":"44","author":"Moore","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.02.024_bib0200","unstructured":"Januskiene J. European Medicine Agency. Signal management: Sitagliptin\u00a0\u2013\u00a0JANUVIA, JANUMET, EFFICIB, RISTABEN, RISTFOR, TESAVEL, VELMETIA and XELEVIA (DPP-4 inhibitor). Gastrointestinal stenosis and obstruction HLGT. EPITT Reference: 18251. February 23 2015. http:\/\/www.ema.europa.eu.[Accessed April 27, 2020]."},{"key":"10.1016\/j.therap.2020.02.024_bib0205","series-title":"Pharmacovigilance Risk Assessment Committee (PRAC). Minutes of the meeting\u00a0\u2013\u00a05\u20138 October 2015","author":"European Medicine Agency","year":"2015"},{"key":"10.1016\/j.therap.2020.02.024_bib0210","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s13340-016-0261-3","article-title":"Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study","volume":"7","author":"Bennett","year":"2016","journal-title":"Diabetol Int"},{"key":"10.1016\/j.therap.2020.02.024_bib0215","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2982.2007.01079.x","article-title":"GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome","volume":"20","author":"Hellstr\u00f6m","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.therap.2020.02.024_bib0220","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gut.2004.059741","article-title":"Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans","volume":"55","author":"Schirra","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.therap.2020.02.024_bib0225","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1210\/jcem.87.7.8584","article-title":"Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor","volume":"87","author":"Brubaker","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.therap.2020.02.024_bib0230","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000051874","article-title":"Intestinal proliferation and delayed intestinal transit in a patient with a GLP-1-, GLP-2- and PYY-producing neuroendocrine carcinoma","volume":"63","author":"Byrne","year":"2001","journal-title":"Digestion"},{"key":"10.1016\/j.therap.2020.02.024_bib0235","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.diabet.2017.05.009","article-title":"Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy","volume":"43","author":"Nakatani","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.therap.2020.02.024_bib0240","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.nutr.26.061505.111223","article-title":"Glucagon-like Peptide-2","volume":"26","author":"Estall","year":"2006","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.therap.2020.02.024_bib0245","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/gut.28.2.166","article-title":"Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers","volume":"28","author":"Savage","year":"1987","journal-title":"Gut"},{"key":"10.1016\/j.therap.2020.02.024_bib0250","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1146\/annurev-physiol-021113-170317","article-title":"Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2","volume":"76","author":"Drucker","year":"2014","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.therap.2020.02.024_bib0255","doi-asserted-by":"crossref","first-page":"G1038","DOI":"10.1152\/ajpgi.00282.2010","article-title":"Role of cholinergic neurons in the motor effects of glucagon-like peptide-2 in mouse colon","volume":"299","author":"Amato","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.therap.2020.02.024_bib0260","series-title":"Product information: GATTEX\u00ae subcutaneous injection, teduglutide subcutaneous injection","year":"2019"},{"key":"10.1016\/j.therap.2020.02.024_bib0265","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40264-015-0351-3","article-title":"An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies","volume":"39","author":"Maci\u00e1-Mart\u00ednez","year":"2016","journal-title":"Drug Saf"},{"key":"10.1016\/j.therap.2020.02.024_bib0270","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2020.02.024_bib0275","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"B\u00e9gaud","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.therap.2020.02.024_bib0280","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572030086X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572030086X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:51Z","timestamp":1758567231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059572030086X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S004059572030086X"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2020.02.024","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incretin-based drugs and intestinal obstruction: A pharmacovigilance study","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2020.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}